These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 24336032

  • 21. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR, Vanrenterghem Y.
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [Abstract] [Full Text] [Related]

  • 22. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA, Nagib AM, Donia AF, Denewar AA, Abu-Elmagd MM, Abbas MH, Abdel-Rahman AM, Mashaly ME, Elsaftawy MM, Ghoneim MA.
    Saudi J Kidney Dis Transpl; 2018 Nov; 29(6):1267-1273. PubMed ID: 30588956
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T, Omoto K, Shimizu T, Ishida H, Tanabe K.
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH, Chadban SJ, Campbell S, Dent H, Russ GR, McDonald SP.
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J, del Castillo D, Cabello M, Pallardó L, Grinyó JM, Fernández AM, Brunet M.
    Transplantation; 2010 Apr 27; 89(8):994-1000. PubMed ID: 20335831
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
    Meçule A, Tinti F, Poli L, Bachetoni A, Umbro I, Nofroni I, Lai Q, Pretagostini R, Berloco PB, Mitterhofer AP.
    Transplant Proc; 2011 May 27; 43(4):1024-7. PubMed ID: 21620042
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial.
    Ravaioli M, Neri F, Lazzarotto T, Bertuzzo VR, Di Gioia P, Stacchini G, Morelli MC, Ercolani G, Cescon M, Chiereghin A, Del Gaudio M, Cucchetti A, Pinna AD.
    Transplantation; 2015 Aug 27; 99(8):1625-32. PubMed ID: 25757214
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.
    Soliman KM, Posadas Salas AC, Taber DJ.
    Exp Clin Transplant; 2019 Dec 27; 17(6):707-713. PubMed ID: 30570456
    [Abstract] [Full Text] [Related]

  • 36. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS, Vasilescu R, Tanriover B, Coppleson Y, Rekhtman Y, Hardy MA, Dube G, Crew RJ, Ratner LE, Cohen DJ, Mohan S.
    Transplantation; 2014 Mar 27; 97(6):642-7. PubMed ID: 24637863
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Falsely abnormally elevated blood trough concentration of tacrolimus measured by antibody-conjugated magnetic immunoassay in a renal transplant recipient: a case report.
    Toraishi T, Takeuchi H, Nakamura Y, Konno O, Yokoyama T, Iwamoto H, Hama K, Hirano T, Unezaki S, Okuyama K, Shimazu M.
    Transplant Proc; 2012 Jan 27; 44(1):134-6. PubMed ID: 22310597
    [Abstract] [Full Text] [Related]

  • 39. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y, Hama K, Katayama H, Soga A, Toraishi T, Yokoyama T, Kihara Y, Jojima Y, Konno O, Iwamoto H, Takeuchi H, Hirano T, Shimazu M.
    Transplant Proc; 2012 Jan 27; 44(1):124-7. PubMed ID: 22310595
    [Abstract] [Full Text] [Related]

  • 40. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA, Sinha A, Haas M, Choi J, Mirocha J, Kahwaji J, Peng A, Villicana R, Jordan SC.
    Transplantation; 2015 Jul 27; 99(7):1423-30. PubMed ID: 25606792
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.